BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechanisms to improve patient survival benefit from thes...
Main Authors: | Brenden Chen, Christine Tardell, Brian Higgins, Kathryn Packman, John F Boylan, Huifeng Niu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22880048/?tool=EBI |
Similar Items
-
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
by: Patrick A. Ott, et al.
Published: (2013-10-01) -
The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations
by: Michael P. Mullane
Published: (2014-01-01) -
Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot
by: Eimei Iwama, et al.
Published: (2015-10-01) -
Identification of KIT as a Suppressor of BRAFV600E-Mutant Melanoma
by: Neiswender, James V.
Published: (2017) -
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
by: Andrews, L.J, et al.
Published: (2022)